SENSIGHT is being built on a rapidly growing deep and broad set of anonymised and de-identified patient data derived from the research partnerships Sensyne has entered into with NHS Trusts and US health systems that currently covers 22.5 million patients across a range of disease areas.
Reducing clinical trial attrition by quickly assessing feasibility.
Reducing cost and duration of clinical trials by optimising trial design.
Accelerating discovery and development of new drugs.
Refining market access strategies for new or existing drugs.
Referral support for companies interested in clinical trials
Access to unique high quality deep longitudinal real world data insights across a broad range of disease areas. Initially covering 2 million patients and anticipated to grow rapidly to 10 million patients by the end of 2021.
Ability to create, validate and explore curated patient cohorts, Our ambition is for SENSIGHT to become the world’s leading data analytics platform for life sciences and healthcare research across multiple therapeutic areas, unrivalled in breadth and depth of available data.
Easy to use analysis tools for patient stratification, disease progression, building and running synthetic control arms and image quantification.
Researchers can communicate and collaborate with each other on the platform - creating a virtual scientific research network that connects healthcare, life sciences and academic professionals and organisations.
No direct patient data is, or ever will be, shared on SENSIGHT. The platform instead rapidly interrogates Sensyne’s deep diverse datasets and delivers intelligent analytics and data-driven insights, not the data itself. Subscribers will be screened to ensure legitimate interest, with only those in accredited companies and organisations being accepted.